Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIFT Therapy in Newly Diagnosed Diffuse Midline Glioma
NCT07796061Phase 1Recruiting
- Sponsor
- Children's National Research Institute
- Start
- Oct 2026
- Primary completion
- Dec 2031
- Countries
- 1
01
Overview
Phase 1, open-label trial in diffuse midline glioma (DMG) (2 arms), sponsored by Children's National Research Institute. Primary endpoints: Safety Evaluation at 28 days and Feasibility evaluation at 28 days. Started Oct 2026; status: recruiting.
02
Conditions
diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT07796061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07796061.